Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
GUILDFORD, England, October 8, 2013 /PRNewswire/ --
MedPharm Ltd (http://www.medpharm.co.uk), the topical and transdermal formulation development specialist, today announced the opening of a new £0.5m GMP facility in Guildford as it strives to double turnover and increase market share over the next 5 years.
Dr Andrew Muddle, CEO, commented: "The opening of the new site is a huge milestone for our business. We can now offer a true one stop shop for formulation development, all provided in house. From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements. In particular, the bespoke clinical trials supplies production facility, regulated by state of the art monitoring systems, will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms. These include liquids, semi-solid gels, creams and ointments, as well as inhaled products, sprays and transdermal patches to name but a few".
The investment adds a new microbiology laboratory, clean room suites, a dedicated ICH stability testing area and a quality control and performance testing laboratories to support Phase I and II clinical manufacture. The facility also allows for the manufacture of highly potent compounds up to OEB 4 level with a manufacturing batch scale of up to 50kg and primary packaging, labelling and randomisation services.
"This new capability allows MedPharm to ensure a smooth transfer from development and preclinical studies to clinical manufacturing by taking all the services in house on one site. This has the potential to significantly decrease project time lines and costs for clients" added MedPharm's CSO and COO , Professor Marc Brown.
The expansion was funded partly with assistance from Lloyds Commercial Banking.
About the company:
MedPharm is a specialist pharmaceutical development company that is recognized internationally for its expertise in transdermal and topical (skin, nail, nose, lungs and other mucosal membranes) drug delivery systems and formulations. Established in 1999 and with numerous high profile customers, MedPharm has built a worldwide reputation for its unique and highly specialized service in contract research and development; together with expert project management. Projects range from simple feasibility tests, formulation and dosage form design and optimisation, through to preparation of GMP clinical supplies for Phase I/II trials with guaranteed subsequent smooth transfer through to commercial manufacturing sites. . The company operates a hybrid business model, with a CRO business and a development programme with a substantial patent portfolio of novel topical and transdermal drug delivery systems. These systems include MedSpray®, MedTherm™ and, most recently AquaRMed. It has produced these innovations by exploiting its internal product development expertise, with a particular focus on dermatology. The company is actively seeking to license these technologies to third parties for developing their own compounds in non-competing indications. MedPharm's laboratories in the UK are routinely inspected by Regulatory Authorities to ensure that its Quality System meets the requirements for GMP and GLP.
MedPharm's aim is to continue to build on its reputation as a specialist transdermal and topical pharmaceutical development company concentrating on the development and commercial exploitation of specialist products for dermatology and other topical and transdermal indications.
More information can be found at http://www.medpharm.co.uk
Contact the business development team: firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.